◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › N › NVCR

Novocure Ltd (NVCR) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-06

Novocure Ltd (NVCR) operates in the MEDICAL DEVICES industry and is headquartered in Baar, Switzerland with about 1,605 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, NVCR reported $655M in revenue and ($136M) in net income.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.

Interactive charts & full statements → Open the NVCR valuation workbench →

NVCR Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$699M	$655M	$605M	$509M	$538M	$535M	$494M	$351M	$248M	$177M	$83M	$33M	$15M	$10M
Gross Profit	$532M	$488M	$468M	$381M	$423M	$420M	$388M	$263M	$168M	$121M	$37M	$12M	$5M	$3M
Gross Margin %	76.1%	74.5%	77.3%	74.8%	78.6%	78.5%	78.5%	74.8%	67.7%	68.6%	44.2%	37.7%	35.2%	32.3%
Operating Income (EBIT)	($154M)	($154M)	($170M)	($233M)	($90M)	($44M)	$30M	($1M)	($34M)	($39M)	($115M)	($104M)	($80M)	($64M)
Operating Margin %	-22.1%	-23.5%	-28.2%	-45.7%	-16.6%	-8.3%	6.2%	-0.3%	-13.6%	-22.2%	-139.1%	-314.3%	-517.5%	-622.2%
Net Income	($149M)	($136M)	($169M)	($207M)	($93M)	($58M)	$20M	($7M)	($64M)	($62M)	($132M)	($112M)	($81M)	($77M)
Net Margin %	-21.2%	-20.8%	-27.9%	-40.6%	-17.2%	-10.9%	4.0%	-2.1%	-25.6%	-34.8%	-159.1%	-337.2%	-520.9%	-746.9%
EBITDA	($134M)	($119M)	($110M)	($177M)	($79M)	($34M)	$45M	$8M	($25M)	($32M)	($110M)	($101M)	($78M)	($63M)
Earnings Per Share (EPS)	$-1.31	$-1.22	$-1.56	$-1.95	$-0.88	$-0.56	$0.18	$-0.07	$-0.69	$-0.70	$-1.54	$-1.34	$-1.12	$-6.43
Shares Outstanding (M)	116M	111M	108M	106M	105M	103M	109M	97M	92M	89M	86M	84M	72M	12M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVCR Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$184M	$174M	$174M	$167M	$159M	$155M	$161M	$155M
Gross Profit	$142M	$135M	$132M	$122M	$117M	$116M	$128M	$120M
Gross Margin %	77.6%	77.6%	75.8%	73.2%	73.9%	75.1%	79.2%	77.2%
Operating Income (EBIT)	($11M)	($67M)	($40M)	($36M)	($40M)	($38M)	($63M)	($32M)
Operating Margin %	-5.8%	-38.7%	-23.2%	-21.5%	-24.9%	-24.4%	-39.2%	-20.7%
Net Income	($16M)	($71M)	($24M)	($37M)	($40M)	($34M)	($66M)	($31M)
Net Margin %	-8.5%	-40.9%	-14.1%	-22.3%	-25.3%	-22.1%	-40.9%	-19.7%
EBITDA	($11M)	($63M)	($34M)	($26M)	($32M)	($27M)	($11M)	($19M)
Earnings Per Share (EPS)	$-0.13	$-0.62	$-0.22	$-0.33	$-0.36	$-0.31	$-0.61	$-0.28
Shares Outstanding (M)	116M	114M	111M	112M	112M	110M	108M	108M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVCR Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	$1M	($49M)	($26M)	($73M)	$31M	$83M	$99M	$27M	($2M)	($33M)	($108M)	($100M)	($74M)	($53M)
Capital Expenditures (CapEx)	$23M	$27M	$43M	$27M	$21M	$24M	$15M	$10M	$7M	$7M	$18M	$10M	$2M	$4M
Free Cash Flow (FCF)	($21M)	($76M)	($69M)	($100M)	$9M	$59M	$84M	$16M	($9M)	($40M)	($125M)	($110M)	($77M)	($56M)
FCF Margin %	-3.0%	-11.6%	-11.4%	-19.7%	1.8%	10.9%	17.0%	4.6%	-3.5%	-22.9%	-151.1%	-332.9%	-494.3%	-543.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVCR Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$12M	($14M)	($18M)	$21M	($16M)	($36M)	($3M)	$10M
Capital Expenditures (CapEx)	$7M	$5M	$5M	$6M	$5M	$11M	$9M	$11M
Free Cash Flow (FCF)	$6M	($19M)	($23M)	$15M	($21M)	($46M)	($12M)	$0M
FCF Margin %	3.0%	-10.7%	-13.1%	8.9%	-13.5%	-29.9%	-7.7%	-0.2%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NVCR Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$795M	$804M	$1.2B	$1.1B	$1.2B	$1.1B	$1.1B	$479M	$340M	$265M	$282M	$307M	$118M	$189M
Cash & Cash Equivalents	$94M	$103M	$164M	$241M	$115M	$209M	$246M	$177M	$141M	$79M	$100M	$119M	$58M	$176M
Total Liabilities	$457M	$464M	$881M	$784M	$750M	$729M	$575M	$262M	$228M	$152M	$140M	$57M	$20M	$17M
Total Debt (Short + Long-Term)	$196M	$207M	$663M	$654M	$639M	$632M	$436M	$187M	$149M	$195M	$193M	$47M	$1M	$1M
Total Shareholders' Equity	$338M	$340M	$360M	$362M	$441M	$410M	$477M	$218M	$112M	$114M	$142M	$251M	$98M	$172M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NVCR viewer.

Other Companies in MEDICAL DEVICES

INSP · Inspire Medical Systems Inc — $2 billion
UFPT · UFP Technologies Inc — $2 billion
BFLY · Butterfly Network Inc — $2 billion
ESTA · Establishment Labs Holdings Inc — $2 billion
ATEC · Alphatec Holdings Inc — $2 billion
CNMD · CONMED Corporation — $1 billion
IART · Integra LifeSciences Holdings — $1 billion
TNDM · Tandem Diabetes Care Inc — $1 billion

← NVC All “N” companies NVCT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.